Therefore, we investigated whether combination therapy that brings together three stings of power, PD1 blockade and GITR targeting with a vaccine would enhance tumor-specific CD8+ T immunity in a stringent, palpable B16 treatment model. This evidence concerns the gene PDCD1 and neoplasm.